This study aims to confirm cancer-related serological profile of ZRF1 and KRR1 in large-scale ELISA screening of their recombinant analogues with sera of breast cancer patients of different histological types and tumor grades compared with sera of healthy individuals. This evidence concerns the gene DNAJC2 and breast cancer.